EPICONCEPT UK LIMITED

Their core work

Epiconcept UK is the British arm of a specialist epidemiology technology SME that builds data collection, surveillance and analysis platforms for public health research. They work on vaccine effectiveness studies, infectious disease surveillance and pandemic preparedness — typically providing the technical backbone (data systems, study coordination, epidemiological methods) that lets large multi-country research networks collect and compare clinical and virological data. Their value is practical: when a European consortium needs to pool patient data across dozens of hospitals and primary care sites under a single protocol, Epiconcept is the kind of partner that makes that logistically possible.

What they specialise in

How they've shifted over time

Their first H2020 engagement (I-MOVE-plus, 2015-2018) was squarely about vaccine effectiveness measurement in Europe — a relatively focused epidemiological monitoring topic. From 2020 onwards the work broadened sharply under COVID-19 pressure: I-MOVE-COVID-19 added primary-care and hospital network data pooling, and PANDEM-2 moved them into pandemic preparedness IT, simulation and responder communication. The clear trajectory is from routine vaccine surveillance toward broader pandemic-response infrastructure.

They are positioning themselves as a go-to technical partner for pandemic-scale surveillance and response systems, not just seasonal vaccine studies.

How they like to work

They consistently join as a third party rather than coordinating, which suggests they are a specialist subcontractor plugged into larger epidemiological consortia (likely via Epiconcept's French parent or academic partners). Across three projects they have worked with 59 partners in 20 countries, so they operate as a connective node in broad European networks rather than in small tight teams. Expect them to deliver a defined technical or methodological slice rather than lead scientific direction.

59 partners across 20 countries, all within European public-health research networks. The footprint is pan-European with no single national anchor beyond the UK base.

What sets them apart

Few SMEs combine hands-on epidemiological software expertise with a track record across both routine vaccine surveillance and live pandemic response. Partner with them when a consortium needs someone who has already built multi-country data pooling systems for influenza and COVID-19 and can repeat the pattern for the next outbreak. They are specialists, not generalists — valuable precisely because their three H2020 projects form a coherent line of work rather than a scattered portfolio.

Highlights from their portfolio

• I-MOVE-COVID-19
  A direct COVID-19 research network covering primary care, hospitals, and virological surveillance — their most substantive scientific contribution.
• PANDEM-2
  Moves them beyond epidemiology into pandemic preparedness IT and responder-facing tools, signalling a strategic broadening.
• I-MOVE-plus
  The founding project that built their pan-European vaccine effectiveness platform and established the network they still work through.